Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Launched by INTELLIA THERAPEUTICS · Jan 24, 2023

Keywords

ClinConnect Summary

This clinical trial is designed to follow up with patients who have previously received an experimental treatment called NTLA-2001. This treatment is being studied for its effects on certain conditions related to the buildup of proteins in the body, which can affect the nerves and heart. The goal of this follow-up study is to observe the long-term effects of NTLA-2001 on these patients.

To participate in this study, individuals should have completed or stopped participating in a previous trial where they received NTLA-2001. They also need to give their permission to be part of this long-term follow-up. There are no specific exclusions, so if someone meets the criteria, they can join. Participants will be monitored to see how they are doing over time, helping researchers understand the lasting impact of the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.
• • 2. A subject has provided informed consent for the LTFU study.
• Exclusion Criteria:
• • None